Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215852 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
A Phase 2 study, sponsored by AIM ImmunoTech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00215852 is a Phase 2 study that was terminated before completion, run by AIM ImmunoTech. The registered enrollment target is 17 participants.
The verdict
NCT00215852, a Phase 2 study, was terminated before completion, sponsored by AIM ImmunoTech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
To conduct a randomized dose-ranging study to evaluate the safety and activity of orally administered low dose interferon alfa-n3 as an immunomodulator in subjects with asymptomatic HIV-1 infection. The primary endpoints of the study will include an increase or upregulation in genes known to be mediators of interferon response. Secondary endpoints will include the absolute CD4 count and plasma HIV RNA levels.
Interventions
- DRUG Alferon LDO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00215852
The ClinicalTrials.gov registry entry for NCT00215852 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIM ImmunoTech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alferon LDO is the first listed.
NCT00215852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00215852 about?
NCT00215852 is a clinical study titled "A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects". To conduct a randomized dose-ranging study to evaluate the safety and activity of orally administered low dose interferon alfa-n3 as an immunomodulator in subjects with asymptomatic HIV-1 infection. The primary endpoints of the study will include an increase or upregulation in genes known to be medi...
What is the current status of trial NCT00215852?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2005-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00215852?
The interventions under investigation include: Alferon LDO (DRUG).
Who is sponsoring clinical trial NCT00215852?
This trial is sponsored by AIM ImmunoTech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.